An evaluation of gabapentin and pregabalin usage in the treatment of neuropathic pain related to spinal cord injury

Aim: In the present study, we aimed to systematically evaluate the effects of gabapentin and pregabalin, which are believed to be safe and well-tolerated and have analgesic, anticonvulsant, and anxiolytic effects, in the treatment of neuropathic pain after spinal cord injury despite their high side effect profiles.Material and Methods: A literature search of numerous electronic databases was performed. A combination of key words was used to retrieve studies published until November 1, 2018 correlated with the point of interest. The key words used were as follows: “spinal cord injury,” “neuropathic pain,” “gabapentin,” and “pregabalin.” Studies that met the inclusion criteria and were Level of I clinical trials were included in the study. The included studies were statistically evaluated.Results: In total, 125,515 publications were retrieved using the aforementioned key words. 19 studies on the use of gabapentin and pregabalin for the treatment of neuropathic pain associated with spinal cord injury were retrieved through.Conclusion: Studies suggested that available treatment modalities did not provide satisfactory outcomes for patients with neuropathic pain related to spinal cord injury. However, gabapentin and pregabalin were preferred as the first-line drugs in the treatment of neuropathic pain. The efficacy of gabapentin in the treatment of neuropathic pain after spinal cord injury has only been investigated in a few recent studies; data in these studies are not sufficiently clear and will need further clarification.

PDF

___

1. Wu-Fienberg Y, Henzel MK, Richmond MA, et al. Impact of interdisciplinary rounds in the spinal cord injury unit on relational coordination for patients with pressure injury: A pilot study. J Spinal Cord Med 2018; 6:1-6.
2. Peacock S, Patel S. Cultural influences on pain. Rev Pain 2008;1:6-9.
3. Grau JW, Huang YJ, Turtle JD, et al. Whenpain hurts: Nociceptive stimulation induces a state of maladaptive plasticity and impairs recovery after spinal cord injury. J Neurotrauma 2017;34:1873-90.
4. Zhao T, Yishmaan BL, Lin D, et al. Is delayed surgeryafter unsuccessfulconservative treatment beneficial for spinal cord injuryfollowing whiplash? A retrospective study in elderly patients.Med Sci Monit 2018;24:2818-24.
5. Furlan JC, Gulasingam S, Craven BC. The health economics of the spinal cord injury or disease among veterans of war: A systematic review. J Spinal Cord Med 2017;40:649-64.
6. Yilmaz I, Ulugol A. The effect of nitric oxide synthase inhibitors on the development of analgesic tolerance to dipyrone in mice. Int J Neurosurg 2009;119:755-64.
7. Gray P. Pregabalin in the management of central neuropathic pain. Expert Opin Pharmacother 2007;8:3035-41.
8. Siddall PJ, Loeser JD. Pain following spinal cord injury.Spinal Cord 2001;39:63-73.
9. Siddall PJ, McClelland JM, Rutkowski SB, et al. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain 2003;103:249-57.
10. Falci S, Indeck C, Barnkow D. Spinal cord injury below-level neuropathic pain relief with dorsal root entry zone microcoagulation performed caudal to level of complete spinal cord transection. J Neurosurg Spine 2018;28:612-20.
11. Jahangiri FR. Intraoperative neurophysiological monitoring (IONM) for cordotomy procedures. Neurodiagn J. 2015;55:169-79.
12. Curtis E, Martin JR, Gabel B, et al. A first-in-human, Phase I study of neural stem cell transplantation for chronic spinal cord injury. Cell Stem Cell 2018;22:941-50.
13. Musselman KE, Shah M, Zariffa J. Rehabilitation technologies and interventions for individuals with spinal cord injury: Translational potential of current trends.J NeuroengRehabil. 2018;15:40.
14. Nardone R, Höller Y, Taylor A, et al. et al. Noninvasive spinal cord stimulation: Technical aspects and therapeutic applications. Neuromodulation 2015;18:580-91.
15. Cushman DM, Thomas K, Mukherjee D, Jet al. Perceived quality of life with spinal cord injury: A comparison between emergency medicine and physical medicine and rehabilitation physicians. PM R 2015;7:962-9.
16. Iqbal Z, Azmi S, Yadav R, et al. Diabetic peripheral neuropathy: Epidemiology, diagnosis, and pharmacotherapy. ClinTher 2018;40:828-9.
17. Kumru H, Benito-Penalva J, Kofler M, et al. Analgesic effect of intrathecalbaclofen bolus on neuropathic pain in spinal cord injury patients. Brain Res Bull 2018;140:205-11.
18. Wiffen PJ, McQuay HJ, Edwards JE, et al. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2005;20:CD005452.
19. Karaarslan N, Yilmaz I, Sirin DY, et al. Pregabalin treatment for neuropathic pain may damage intervertebral disc tissue.ExpTher Med 2018;16:1259-65.
20. Karaarslan N, Yilmaz I, Ozbek H, et al.Systematic evaluation of promising clinical trials-Gene silencing for the treatment of glioblastoma. Turk Neurosurg 2018;6.
21. Karaarslan N, Yilmaz I, Akgun FS, et al. Systematic evaluation of desmopressinapplied to the patients with aneurysmal subarachnoid haemorrhage in the light of the literature. Turk Neurosurg 2018;9.
22. Topuk S, Akyuva Y, Karaaslan N, et al. Is it possible to treat osteosarcoma using oligonucleotides confined into controlled release drug delivery systems?Curr Pharm Biotechnol 2017;18:516-22.
23. Akgun FS, Karaarslan N, Yilmaz I, et al. Systematic evaluation of adverse reactions that may occur after injection of type-a botulinum toxin in patients with spasmodic torticollis admitted to emergency department. Merit Res J Med Sci 2018;6:68-72.
24. Akyuva Y, Karaarslan N, Yilmaz I, et al. Will intervertebral disc diseases be prevented by siRNA or miRNA-based genomic treatment modalities? Merit Res J Med Med Sci 2018;6:6-15.
25. Karaarslan N, Kaya YE, Yilmaz I, et al. Will it be possible to prevent lumbar degenerative disc diseases in the future by means of vitamin D receptor gene manupulation? Merit Res J Med Med Sci 2017;5:500-10.
26. Gruenthal M, Mueller M, Olson WL, et al. Gabapentinfor the treatment of spasticity in patients with spinal cord injury.Spinal Cord 1997;35:686-9.
27. Tai Q, Kirshblum S, Chen B, et al. Gabapentinin the treatment of neuropathic pain afterspinal cord injury: A prospective, randomized, double-blind, crossover trial. J Spinal Cord Med 2002;25:100-5.
28. Ahn SH, Park HW, Lee BS, et al. Gabapentineffect on neuropathic pain compared among patients withspinal cord injuryand different durations of symptoms.Spine (Phila Pa 1976). 2003;28:341-7.
29. Levendoglu F, Ogün CO, Ozerbil O, et al. Gabapentin is a first line drug for the treatment of neuropathic pain inspinal cord injury.Spine (Phila Pa 1976) 2004;29:743-51.
30. Siddall PJ, Cousins MJ, Otte A, et al. Pregabalinin central neuropathic pain associated withspinal cord injury: A placebo-controlled trial. Neurology 2006;67:1792-800.
31. Rintala DH, Holmes SA, Courtade D, et al. Comparison of the effectiveness of amitriptyline andgabapentinon chronic neuropathic pain in persons withspinal cord injury. Arch Phys Med Rehabil 2007;88:1547-60.
32. Silver M, Blum D, Grainger J, Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manage 2007;34:446-54.
33. Vranken JH, Dijkgraaf MG, Kruis MR, et al. Pregabalinin patients with central neuropathic pain: A randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 2008;136:150-7.
34. Tzellos TG, Papazisis G, Amaniti E, et al. Efficacy of pregabalin and gabapentin for neuropathic pain inspinal cordinjury: An evidence-based evaluation of the literature. Eur J Clin Pharmacol 2008;64:851-8.
35. Norrbrink C, Lundeberg T. Tramadol in neuropathic pain afterspinal cord injury: A randomized, double-blind, placebo-controlled trial. Clin J Pain 2009;25:177-84.
36. Amr YM. Multi-day low dose ketamine infusion as adjuvant to oralgabapentininspinal cord injuryrelated chronic pain: A prospective, randomized, double blind trial. Pain Physician 2010;13:245-9.
37. Parsons B, Sanin L, Yang R, et al. Efficacy and safety ofpregabalinin patients withspinal cord injury: A pooled analysis. Curr Med Res Opin 2013;29:1675-83.
38. Cardenas DD, Nieshoff EC, Suda K, et al. A randomized trial ofpregabalinin patients with neuropathic pain due to spinal cord injury. Neurology 2013;80:533-9.
39. Min K, Oh Y, Lee SH, et al. Symptom-based treatment of neuropathic pain in spinalcord-injured patients: A randomized crossover clinical trial. Am J Phys Med Rehabil 2016;95:330-8.
40. Schug SA, Parsons B, Almas M, et al. Effect of concomitant pain medications on response to pregabalin in patients with postherpetic neuralgia or spinal cord injury-related neuropathic pain. Pain Physician 2017;20:E53-E63.
41. Vollert J, Magerl W, Baron R, et al. Pathophysiological mechanisms of neuropathic pain: Comparison of sensory phenotypes in patients and human surrogate pain models.Pain 2018;159:1090-102.